Identification, synthesis and evaluation of SARS-CoV and MERS-CoV 3C-like protease inhibitors

Article abstract of DOI:10.1016/j.bmc.2016.05.013

Severe acute respiratory syndrome (SARS) led to a life-threatening form of atypical pneumonia in late 2002. Following that, Middle East Respiratory Syndrome (MERS-CoV) has recently emerged, killing about 36% of patients infected globally, mainly in Saudi Arabia and South Korea. Based on a scaffold we reported for inhibiting neuraminidase (NA), we synthesized the analogues and identified compounds with low micromolar inhibitory activity against 3CL^pro of SARS-CoV and MERS-CoV. Docking studies show that a carboxylate present at either R¹ or R⁴ destabilizes the oxyanion hole in the 3CL^pro. Interestingly, 3f, 3g and 3m could inhibit both NA and 3CL^pro and serve as a starting point to develop broad-spectrum antiviral agents.

Full text of DOI:10.1016/j.bmc.2016.05.013

Accepted Manuscript
Identification, synthesis and evaluation of SARS-CoV and MERS-CoV 3C-like
protease inhibitors
Vathan Kumar, Kian-Pin Tan, Ying-Ming Wang, Sheng-Wei Lin, Po-Huang
Liang
PII:
S0968-0896(16)30336-4
DOI:
http://dx.doi.org/10.1016/j.bmc.2016.05.013
BMC 12997
Reference:
Bioorganic & Medicinal Chemistry
To appear in:
Received Date:
Revised Date:
Accepted Date:
31 March 2016
10 May 2016
11 May 2016
Please cite this article as: Kumar, V., Tan, K-P., Wang, Y-M., Lin, S-W., Liang, P-H., Identification, synthesis and
evaluation of SARS-CoV and MERS-CoV 3C-like protease inhibitors, Bioorganic & Medicinal Chemistry (2016),
doi: http://dx.doi.org/10.1016/j.bmc.2016.05.013
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers
we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and
review of the resulting proof before it is published in its final form. Please note that during the production process
errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Identification, synthesis and evaluation of SARS-CoV and MERS-CoV 3C-like
protease inhibitors
Vathan Kumar,a Kian-Pin Tan,a Ying-Ming Wang,a Sheng-Wei Lin,a Po-Huang Liang*,a,b
a Institute of Biological Chemistry, Academia Sinica, Taipei 115, Taiwan
b Institute of Biochemical Sciences, National Taiwan University, Taipei 106, Taiwan
Corresponding author. Tel.: +886-2-2366-5539; fax: +886-2-2363-5038
E-mail address: phliang@gate.sinica.edu.tw (P-H Liang)
Keywords:
MERS-CoV
SARS-Cov
3CLpro
Coronavirus
Pyrazolone
Abstract
Severe acute respiratory syndrome (SARS) led to a life-threatening form of atypical pneumonia in late
2002. Following that, Middle East Respiratory Syndrome (MERS-CoV) has recently emerged, killing
about 36% of patients infected globally, mainly in Saudi Arabia and South Korea. Based on a scaffold
we reported for inhibiting neuraminidase (NA), we synthesized the analogues and identified compounds
with low micromolar inhibitory activity against 3CLpro of SARS-CoV and MERS-CoV. Docking studies
show that a carboxylate present at either R1 or R4 destabilizes the oxyanion hole in the 3CLpro.
Interestingly, 3f, 3g and 3m could inhibit both NA and 3CLpro and serve as a starting point to develop
broad-spectrum antiviral agents.
1

1. Introduction
Severe acute respiratory syndrome (SARS) led to a life-threatening form of atypical pneumonia
in late 2002. In March 2003, the causative agent was identified and named as SARS coronavirus
(SARS-CoV). SARS-CoV belongs to the genus Coronaviridae, and is an enveloped, positive-stranded
virus with ~30,000 nucleotides.[1] Viral genome encodes two polyproteins, pp1a (~490 kDa) and pp1ab
(~790 kDa). 3C-like protease (3CLpro), the main protease, and papain-like protease (PLpro) cleave these
polyproteins to generate non-structural proteins essential for the viral replication.[2, 3] Due to its vital role
in replication, 3CLpro is an attractive drug target. Many inhibitors were discovered from high throughput
screening and structure-based rational design.[4-10]
Although the SARS-CoV infection died down soon, another human CoV associated with the
Middle East Respiratory Syndrome (MERS-CoV) has recently emerged, killing about 36% (584 of
1621) of patients infected globally, mainly in Saudi Arabia and South Korea.[11] Due to the similar
maturation pathway, MERS-CoV 3CLpro is also regarded as a target for developing anti-viral drug. The
previously reported SARS-CoV 3CLpro inhibitors cannot potently inhibit MERS-CoV 3CLpro without
modifications, due to the subtle structural differences in their active sites.[12] Though tremendous efforts
have been made to develop inhibitors, therapeutic interventions for the continuous outbreaks of these
deadly CoVs, are yet to reach the market.[13, 14]
While the origin of SARS dates back to early 2003, influenza has a century-old history of affecting
humans. Influenza virus is an enveloped RNA virus that belongs to the orthomyxoviridae family.[15] It
has caused four major pandemics in the last century, namely, 1918 (‘Spanish’ flu, H1N1), 1957 (‘Asian’
flu, H2N2), 1968 (‘Hong Kong’ flu, H3N2), and 1977 (‘Russian’ flu, H1N1).[16] Spanish flu pandemic
claimed about 50 million lives worldwide.[17] Recent outbreak of H7N9 in China along with
A/Shanghai/1/2013 H7N9 virus with R292K mutation is a serious concern.[18, 19] One of the most
accessible targets is neuraminidase (NA), which is essential for the release of viral particle from the cell
2

surface and has been the target for the marketed drugs oseltamivir and zanamivir. We recently
reported new inhibitors of both N1 and N2 type NAs and also showed their anti-viral activities in the
cell-based assay.[20] Due to their structural similarity to our previously discovered SARS-CoV 3CLpro
[21]
inhibitors,
we screened these NA inhibitors on the SARS-CoV and MERS-CoV 3CLpro and
synthesized the analogues of hits to establish the structure-activity-relationship (SAR) on these 3CLpro
as reported herein.
Table 1 IC50 values of analogues against MERS and SARS 3CLpro
Sl. No.
3a
3b
3c
R1
R2
Cl
Cl
H
R3
CH3
CF3
CF3
Ph
R4
3-COOH
3-COOH
3-COOH
3-COOH
H
SARS IC50 (μM)
> 50
MERS IC50 (μM)
>50
COOH
COOH
COOH
COOH
COOH
COOH
COOH
COOH
COOH
H
> 50
>50
> 50
>50
Cl
Cl
Cl
Cl
Cl
Cl
H
44.7 ± 5.1
> 50
>50
3d
3e
CH3
Ph
>50
H
16.4 ± 0.7
20.2 ± 0.3
6.0 ± 1.2
5.8 ± 1.5
> 50
12.2 ± 2.2
10.1 ± 1.8
7.3 ± 2.1
7.4 ± 2.2
>50
3f
Ph
4-F
3g
3h
3i
Ph
4- CH(CH3)2
4- CH(CH3)3
H
Ph
Ph
3j
H
H
Ph
COOH
COOH
H
6.4 ± 1.2
> 50
5.8 ± 1.6
>50
3k
3l
H
H
CH3
Ph
COOH
COOH
COOH
COOH
COOH
COOH
H
41.2 ± 9.5
37.5 ± 0.7
11.7 ± 2.5
8.6 ± 2.1
18.7 ± 4.5
30.7 ± 5.8
> 50
30.3 ± 4.5
> 50
3m
3n
3o
3p
3q
3r
H
Ph
4-F
H
Ph
4- CH(CH3)2
4- CH(CH3)3
4- CN
8.9 ± 1.8
7.7 ± 2.2
9.6 ± 1.6
8.9 ± 1.8
>50
H
Ph
H
Ph
H
Ph
4- OCH3
COOH
No ring A
Ph
3s
All the compounds were synthesized as described in Scheme 1. The pyrazolone core was synthesized
by the condensation of substituted hydrazines with various β-ketoesters. The substituted aldehydes were
synthesized by Meerwein arylation of substituted diazonium salts with furfural.[22] Knoevenagel condensation
3

of substituted aldehydes with various pyrazolones in the presence of a catalytic amount of sodium acetate in
acetic acid yielded the final compounds (50-88%). Chromatographic purification was not required for most of
the compounds as pure compounds could be obtained by methanolic wash.
Scheme 1. Reagents and conditions: (a) NaNO2 / HCl, 0 oC; (b) Furfural, CuCl2.H2O, rt, 48 h; (c) AcOH,
reflux, 24 h; (d) AcONa-AcOH, reflux, 3 h
2. Results and Discussion
Absence of NOE signal between the olefinic and R3 phenyl protons in NMR confirmed pyrazolones as
a single E-isomer.[20] However, methyl substitution at R3 gave geometrical isomers (E/Z) that was inseparable
due to rapid interconversion in solution.[20]
Assay results confirmed that bulkier phenyl group at R3 was essential for the inhibitory activity as
compounds 3a-c, 3e and 3l with CH3 or CF3 at this position were unable to inhibit SARS 3CLpro. Carboxylate
moiety seemed to be an essential component as compound 3j without it at R1 and R4 was inactive. Removal of
R4 carboxylate from 3d (IC50 = 44.7 ± 5.1 µM) but retaining it at R1 resulted in 3f (IC50 = 16.4 ± 0.7 µM) with
4

improved activity. Isosteric replacement of hydrogen by fluorine, 3g (IC50 = 20.2 ± 0.3 µM), caused a slight
drop in activity. However, introducing more lipophilic substitution at R4 improved activity as seen in case of
3h (IC50 = 6.0 ± 1.2 µM) and 3i (IC50 = 5.8 ± 1.5 µM) which had about 3-fold improvement in activity in
comparison with 3f. In contrast, compound 3k (IC50 = 6.4 ± 1.2 µM) with carboxylate only at R4 was 3-fold
and 7-fold more potent compared with 3f and 3m respectively. From these results we conclude that carboxylate
moiety is an important pharmacophore and its presence either at R1 or R4 is critical for the activity as 3k was as
equipotent as 3h and 3i. Chlorine at R2 slightly changed the activity as we observed 2-fold decrease in the
activity of 3m, 3n, 3o and 3p as compared with 3f, 3g, 3h and 3i respectively. Substituent on ring D was also
important. While compounds with electron-withdrawing F or CN (3g, 3q) did not show significant difference
in activity, electron-donating methoxy group (3r) on ring D caused 2-fold drop in activity as compared with 3f
without any substituent.
To study the effect of ring B (furan ring), we replaced it with aromatic system to obtain 3t (Scheme 2).
There was no significant change in the activity of 3t (IC50 = 10.9 ± 1.7 µM) as compared with 3k (IC50 = 6.4 ±
1.2 µM). Ring A of 3k was critical as absence of ring A abolished the activity. We then replaced the rigid link
between ring A and B with an ether linkage (3u) to study the effect. Interestingly, the flexible ether linkage on
3u (IC50 = 9.7 ± 2.0 µM) (Scheme 2) did not alter activity as compared with 3k (IC50 = 6.4 ± 1.2 µM).
5

Scheme 2. Reagents and conditions: (a) Benzyl bromide, dry DMF, 0 oC, 3h; (b) 2f, AcONa-AcOH, reflux, 3
h.
From this SAR study, we reach a conclusion that pharmacophores phenyl at R3 and carboxylate either
at R1 or R4 are essential for the activity. As modification of ring A and B is tolerated well, this can be further
altered to enhance the activity of the compounds.
Observed inhibitory activity against SARS 3CLpro was rationalized by docking simulation using ligand
bound crystal structure (PDB ID: 2ALV). The docking simulation option (Accurate docking) of iGemdock
v2.1 was used to generate 20 solutions. To rationalize the inhibitory effect of these molecules, we must first
understand amino acids that constitute the active site of 3CLpro. Active site of 3CLpro can be divided into
subsites S1-S6. Subsite S1 is made of vital catalytic residue Cys145 which forms catalytic dyad with His41 to
process the polyproteins at eleven sites comprising of conserved Gln followed by small amino acids like Ser,
Ala or Gly.[23] Other vital component of S1 subsite is the oxyanion hole, formed by the interaction of
carboxylate anion of the conserved Gln with Gly143, Ser144 and Cys145, which stabilizes the transition state
during proteolysis.[24, 25] Glu166 at the entrance of the pocket interacts via H-bond with Nɛ2 of the conserved
6

Gln.[24] The S2 and S4 subsites contain hydrophobic and bulky side chains like Val, Leu or Phe. Subsites S5
and S6 are near the surface of the active site and has little role in the substrate binding.
Docking (Figure 1a) shows that compound 3i with 5.8 µM IC50 binds to SARS 3CLpro at S1, S1' and S2
subsites to obstruct substrate binding. At S1 subsite, R1 carboxylate of 3i, as a representative of 3f-3i and
3o-3p, forms H-bonds with Gly143, Ser144 and Cys145 which are the vital residues forming the oxyanion
hole. This prevents efficient cleavage of substrate by obstructing stabilization of the tetrahedral intermediate
formed during the transition state. The carboxylate moiety of these compounds makes an additional H-bond
with His163 at the S1 subsite which is responsible for the specificity of protease towards conserved Gln
residue. The furan ring interacts with the hydrophobic side chain of Leu27 in S1' subsite (not shown).
Due to the hydrophobic nature of S2 subsite, additional alkyl substitution on ring D of 3h, 3i, 3o and 3p
enhances interaction with Met49 and Gln189 through hydrophobic contact. This additional contact seems to be
responsible for 3-fold enhanced inhibition of 3h and 3i compared with 3f and 3g. In addition to hydrophobic
interaction, carbonyl moiety of pyrazolone core in 3f-3i and 3o-3p interacts with His41 through H-bond to
destabilize catalytic dyad. Removal of R2 chlorine, comparing 3f and 3g with 3m and 3n respectively,
unfavorably reorients the molecule to lose H-bonding with His41, Gly143 and Cys145 (Figure S1). This
explains the observed 2-fold drop in activity on removal of chlorine.
7

Glu166
Glu166
a
b
Leu141
Ser144
Leu141
His163
Ser144
S4
S4
His163
S1
S1
Cys145
Cys145
S2
S1’
S1’
S2
His41
His41
Figure 1. Docking of 3i (a) with carboxylate at R1 and 3k (b) with carboxylate at R4 on SARS 3CLpro (PDB
ID: 2ALV) in order for carboxylate to form H-bonds with S1 subsite.
Unlike other compounds in the series, 3k does not seem to occupy S1' subsite (Figure 1b). While the
carboxylate moiety at R4 position interacts with Leu141, Ser144 and His163, R3 phenyl group prefers the
hydrophobic pocket S4. Ring A and B being hydrophobic sit well in S2 subsite. Ring A seems to form a weak
π−π stacking with His41 and thus destabilizes the catalytic dyad. Nitrogen atom in the pyrazolone core seems
to interact with Glu166 located at the entrance of S1 pocket to prevent binding with Gln of the substrate.
Modification of 3k to 3t and 3u did not have significant effect as they prefer binding to similar conformation
(not shown).
Since 3CLpro of both MERS-CoV and SARS-CoV are structurally similar, we expressed MERS-CoV
3CLpro and tested our compounds on it. All SARS-CoV 3CLpro inhibitors were found to inhibit MERS-CoV
3CLpro effectively at low micromolar concentrations. Compounds with bulkier groups,
electron-withdrawing/donating or hydrophobic, substituents on ring D had IC50 around 10 µM. Similar to
SARS 3CLpro, presence of carboxylate moiety seemed essential for inhibiting MERS 3CLpro. Compound 3k
with the carboxylate moiety on ring D was the best inhibitor with IC50 of 5.8 ± 1.6 µM.
8

For the compounds with carboxylate on ring A and unsubstituted or substituted ring D with less bulkier
group like fluorine, removal of chlorine atom caused significant loss of activity by comparing 3f (12.2 ± 2.2
µM) with 3m (30.3 ± 4.5 µM) or fluoro-substituted 3g (10.1 ± 1.8 µM) with 3n (>50 µM). However, in the
presence of bulkier substituents, 3o (8.9 ± 1.8 µM) and 3p (7.7 ± 2.2 µM), lost activity of 3m and 3n was
regained. Removal of chlorine from compounds with bulkier ring D had insignificant effect on inhibition as 3h
(7.3 ± 2.1 µM) and 3i (7.4 ± 2.2 µM) showed activity similar to 3o (8.9 ± 1.8 µM) and 3p (7.7 ± 2.2 µM)
respectively.
Ser147
Leu170
Glu169
His166
Gln195
S4
S1
Cys148
Gln192
S1’
Val193
His41
S2
Leu49
Figure 2. Docking of 3k on MERS-CoV 3CLpro that has smaller S2 site (PDB ID: 4YLU)
The recently solved crystal structure (PDB ID: 4YLU) of MERS-CoV 3CLpro gave insight into the
structural difference between the two 3CLpro.[12] Replacement of residue Thr25 in SARS 3CLpro with Met25 in
case of MERS 3CLpro has shrunk S2 subsite to prevent latter from accommodating bulkier groups. Unlike
SARS-CoV 3CLpro which accommodates ring A and B of 3k, smaller S2 subsite of MERS-CoV 3CLpro
accommodates phenyl moiety at R3 (Figure 2). This smaller size of S2 makes those molecules with the R3
phenyl group fit snugly into the active site of MERS-CoV 3CLpro and should be the reason behind most of the
active compounds being equipotent. In S2 subsite, R3 interacts with His41 via π−π stacking interaction to
perturb the catalytic dyad. At S1 subsite our best inhibitor 3k (Figure 2), with its carboxylate moiety at ring D,
9

interacts with Ser147 to destabilize oxyanion hole. Carbonyl moiety in pyrazolone core also interacts with
Glu169 at the entrance of S2 substite. At S2 subsite, its R3 phenyl formed π−π stacking with His41 to perturb
catalytic dyad. Ring A and B which are primarily hydrophobic interact with the side chains of Leu170, Val193
and Gln195 at S4 subsite. Compound 3f with unsubstituted phenyl group at R3 prefers hydrophobic S2. The
ring C forms T-shaped π−π stacking with His41 and destabilizes the oxyanion hole (Figure S2a). Removal of
chlorine atom caused 3-fold loss in activity of 3m as compared with 3f due to loss of T-shaped π-π stacking
with His41 (Figure S2b). In addition, ring D interacts with hydrophobic side chain of Met25. However, when
ring D is substituted with bulkier groups, removal of chlorine did not make a significant change in activity as
both the molecules maintain similar interactions at S1, S2 and S4 subsites (not shown).
In comparison with inhibiting SARS 3CLpro, most of the active compounds are more potent on MERS
3CLpro. In case of 3g, 3q and 3r, the differences in IC50 reach 2 to 3-fold. The smaller size of S2 in MERS
3CLpro should accommodate the R3 phenyl group and therefore, the substituted ring D is forced to occupy and
make better interaction with the S3 and/or S4 subsites. This point is further illustrated with Figure S3 where
the electron density to reflect the shape and size of the active sites and the transparent carbon skeleton of the
inhibitor are presented.
It is interesting that compounds 3f, 3g and 3m could inhibit H5N1 neuraminidase (NA) with IC50 of
2.8, 2.9, and 13.7 µM, respectively[20] and two 3CLpro at low-micromolar concentrations. Although NA and
3CLpro are not homologous proteins, we observed that they share similar arrangement of the electron-rich
amino acid residues in the active sites. While NA contains arginine triad, 3CLpro contains cysteine-histidine
dyad in the active site and are essential for substrate processing. These active sites are occupied by mainly two
pharmacophores, namely carboxylate and phenyl ring. While carboxylate present at R1 interacts with the vital
arginine residues in case of H5N1 NA,[20] it destabilized the oxyanion hole of MERS 3CLpro (Figure S4).
Another pharmacophore, R3 phenyl interacts with Trp403 and His41 by π−π stacking inside the active site of
NA and 3CLpro respectively.
10

3. Conclusion
Based on a common scaffold, we have optimized the NA inhibitors as inhibitors of 3CLpro of
SARS-CoV and MERS-CoV. Thus, we have discovered broad-spectrum inhibitors effective against the drug
targets of both coronaviruses and avian influenza virus. To the best of our knowledge there is no report
regarding common inhibitors of these targets from coronavirus and influenza virus in the literature. While there
is still no drug for recently emerged MERS-CoV infection, our report raises a possibility of modifying the
known inhibitors of NA to inhibit 3CLpro and vice versa. This approach was tried on MERS by using clinically
approved drugs.[26-28] With the escalating cost of drug discovery, concept of drug repurposing is gaining
importance. Developing an anti-viral agent with broad-spectrum activity might be advantageous to overcome
financial hurdles in the drug discovery. We shall look into modification of the molecules keeping the
pharmacophores intact as it seems to be vital for broad-spectrum activity. Compounds with a pyrazole ring
surrounded by three hydrophobic groups were also reported to inhibit 3C proteases of human picornaviruses,
such as rhinoviruse, enteroviruse, and coxsackieviruse, in addition to 3CLpro of coronaviruses.[29] Efforts are
being made to co-crystallize these compounds with the enzymes. Cell-based assay would be needed to
facilitate further development into more potent inhibitors which could have clinically usefulness.
4. Experimental section
All commercial reagents (Sigma-Aldrich, Acros, Alfa-Aesar) were used as provided and all solvents were
of the highest purity. Proton nuclear magnetic resonance (1H NMR) spectra were recorded on a 400 MHz or
500 MHz spectrometer. Carbon nuclear magnetic resonance (13C NMR) spectra were recorded on a 100 MHz
or 125 MHz spectrometer. Chemical shifts (δ) are reported in parts per million (ppm) relative to solvent, and
the signals are described as br (broad), s (singlet), d (doublet), dd (doublet of doublets), dddd = doublet of
doublets of doublets of doublets, t (triplet), and m (multiplet). Coupling constants (J values) are given in Hz.
High Resolution Mass Spectrometry (HRMS) was obtained by Bruker BioTOF II mass spectrometer and
11

ESI-TOF-MS spectra were recorded. Reaction was monitored on Silica gel 60 F254 thin layer plates (TLC)
from Merck.
4.1 Preparation of substituted furfural:
o
2-amino-4-chloro benzoic acid (1.0 eq.) was diazotized with NaNO2/HCl at 0 – 5 C and to this mixture was
o
gradually added furfural (1.2 eq.) in acetone while maintaining temperature around 0 – 5 C followed by
o
addition of copper (II) chloride (0.3 eq.) in water at once. The reaction mixture was maintained below 5 C for
1 h and then allowed to gradually attain room temperature. The reaction was continued at room temperature for
24 h and the precipitate obtained was filtered and washed with methanol-water mixture to obtain pale yellow
compound.[20]
1
4.1.1
4-chloro-2-(5-formylfuran-2-yl)benzoic acid (1a): H NMR (400 MHz, CDCl3): δ 9.643 (s, 1H),
7.894 (d, J = 8.8 Hz, 1H), 7.680 (d, J = 2.0 Hz, 1H), dd, J = 8.4 Hz, 2.0 Hz, 1H), 7.314 (d, J = 4.0 Hz, 1H),
13
6.821 (d, J = 3.6 Hz, 1H). C NMR (100 MHz, CDCl3): 178.0 (CH), 168.9 (C), 156.5 (C), 152.8 (C), 136.9
(C), 131.1 (CH), 130.2 (C), 130.1 (C), 129.2 (CH), 128.7 (CH), 123.2 (C), 111.6 (CH). HRMS (m/z): [MH-]
calcd. for C12H16ClO4: 248.9966; found 248.9967. (4.14 g, 57%)
4.1.2
2-(5-formylfuran-2-yl)benzoic acid (1b): 1H NMR (400 MHz, CDCl3): δ 9.627 (s, CHO), 7.939
(dd, J = 7.5 Hz, 1.2 Hz, 1H), 7.692 (dd, J = 7.6 Hz, 1.2 Hz, 1H), 7.617 (td, J = 7.6 Hz, 1.6 Hz, 1H), 7.525(td, J
= 7.6 Hz, 1.6 Hz, 1H), 7.318 (d, J = 3.6 Hz, 1H). 13C NMR (100 MHz, CDCl3): 177.8 (CH), 171.8 (C), 157.9
(C), 152.6 (C), 132.2 (CH), 130.1 (CH), 129.9 (CH), 129.7 (CH), 129.6 (C), 129.4 (C), 122.7 (C), 111.4 (CH).
HRMS (m/z): [MH+] calcd. for C12H9O4: 217.0501; found 217.0566. (1.6 g, 20%)
4.2 General procedure for synthesis of pyrazolones:
To 1 eq. of β-ketoester in 50 ml of acetic acid was added 1 eq of substituted phenylhydrazine (for HCl salt 1
eq. of triethylamine was added). The content was refluxed for 24 - 36 h and the contents cooled and solvent
was removed in vacuo. To the precipitate in flask was added ethylacetate to suspend the product and was then
12

filtered to obtain pure compound. Thus obtained product was dried to yield substituted pyrazolone. (Note: In
some case product isolated was tautomer due to keto-enol tautomerism)[20]
1
4.2.1
2,5-diphenyl-2,4-dihydro-3H-pyrazol-3-one (2a): H NMR (500 MHz, CDCl3): δ 8.020 (d, J =
13
8.45 Hz, 2H), 7.769 (m, 2H), 7.470 (m, 5H), 7.254 (t, J = 7.5 Hz, 1H), 3.760 (s, 2H). C NMR (125 MHz,
CDCl3): 170.1 (C), 154.5 (C), 138.1 (C), 130.8 (C), 130.6 (CH), 128.8 (CH), 128.7 (CH), 125.9 (CH), 125.1
(CH), 118.9 (CH), 39.43 (CH2). HRMS (m/z): [MH-] calcd. for C15H11N2O: 235.0882; found 235.0880. (6.12
g, 75%)
1
4.2.2
3-(3-methyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl)benzoic acid (2b): H NMR (400 MHz, MeOD):
δ 8.256 (s, 1H), 7.878 (t, J = 8.0 Hz, 2H), 7.537 (t, J = 8.0 Hz, 2H), 2.200 (s, 3H). 13C NMR (100 MHz,
MeOD): 169.0 (C), 151.7 (C), 138.8 (C), 133.1 (C), 130.3 (CH), 129.9 (C), 128.1 (CH), 127.0 (C), 126.6 (CH),
124.0 (C), 123.3 (CH), 120.9 (C). HRMS (m/z): [MH+] calcd. for C11H10N2O3: 218.0697; found 218.0764.
(0.99 g, 74%)
1
4.2.3
2-(4-methoxyphenyl)-5-phenyl-2,4-dihydro-3H-pyrazol-3-one (2c): H NMR (400 MHz, CDCl3):
13
δ 7.842-7.811 (m, 2H), 7.744-7.720 (m,2H), 7.435-7.419 (m, 3H), 6.955-6.915 (m, 2H). C NMR (100 MHz,
CDCl3): 169.9 (C), 157.1 (C), 154.5 (C), 131.4 (C), 130.9 (C), 130.5 (CH), 128.8 (CH), 125.8 (CH), 120.9
(CH), 114.0 (CH), 55.43 (-OCH3), 39.38 (CH2). HRMS (m/z): [MH+] calcd. for C16H15N2O2: 267.1134; found
267.1128.
4.2.4
4-(5-oxo-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzonitrile (2d): 1H NMR (400 MHz, CDCl3): δ
8.193-8.168 (m,2H), 7.780-7.756 (m,2H), 7.712-7.697 (m, 2H), 7.493-7.449 (m, 3H). 13C NMR (100 MHz,
CDCl3): 170.5 (C), 155.6 (C), 141.5 (C), 133.1 (CH), 131.3 (CH), 130.3 (C), 129.0 (CH), 126.1 (CH), 118.8
(CH), 118.4 (C), 108.0 (C), 39.72 (CH2). HRMS (m/z): [MH+] calcd. for C16H11N3O: 262.0980; found
262.0896.
13

4.2.5
3-(5-oxo-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzoic acid (2f): 1H NMR (400 MHz,
DMSO-d6): δ 13.133 (br, s, COOH), 12.023 (br, s, OH), 8.430 (t, J = 2.2 Hz, 1H), 8.108-8.082 (m, 1H), 7.844
(dd, J = 9.05 Hz, 1.45 Hz, 1H), 7.621 (t, J = 9.9 Hz, 1H), 7.433 (t, J = 9.4 Hz, 2H), 7.348 (t, J = 9.1 Hz, 1H),
13
6.040 (s, 1H). C NMR (100 MHz, DMSO-d6): 167.3 (C), 154.5 (C), 150.5 (C), 139.5 (C), 133.6 (C), 132.1
(C), 129.8 (CH), 129.1 (CH), 128.5 (CH), 126.7 (CH), 125.7 (CH), 125.3 (CH), 121.7 (CH), 85.8 (CH). HRMS
(m/z): [MH+] calcd. for C16H13N2O3: 281.0926; found 281.0917. (1.34 g, 49%)
4.3 Preparation of substituted pyrazolone (3a-3s):
Equimolar amount of 1 and 2 were taken in acetic acid and to this was added catalytic amount of sodium
acetate (0.1 eq.). As the contents were refluxed the product started to precipitate. The reaction was continued
for 3 h and the solvent was removed in vacuo followed by the addition of methanol-water mixture and filtering
crude compound which was again thoroughly washed with methanol-water mixture to remove the impurities
and any traces of starting material to get final compounds. Some compounds were purified using flash column
using ethylacetate: hexane: acetic acid as solvent system.[20]
4.3.1
2-(5-((1-(3-carboxyphenyl)-3-methyl-5-oxo-1,5-dihydro-4H-pyrazol-4-ylidene)methyl)
furan-2-yl)-4-chlorobenzoic acid (3a): 1H NMR (500 MHz, DMSO-d6): δ 13.18 (s, COOH), 8.707 (d, J = 4.0
Hz, 1H), 8.574 (t, J = 2.0 Hz, 1H), 8.199 (ddd, J = 8.1 Hz, 2.5 Hz, 1.0 Hz, 1H), 7.982 (d, J = 2.0 Hz, 1H),
7.769-7.752 ( m, 2H), 7.688 (s, 1H), 7.646 (d, J = 2.5 Hz, 8.0 Hz, 1H), 7.591-7.559 (m, 1H), 7.301 (d, J = 4.0
Hz, 1H). 2.531 (s, 3H). 13C NMR (125 MHz, DMSO-d6): 168.9 (C), 167.5 (C), 162.2 (C), 157.1 (C), 151.6 (C),
151.0 (C), 138.9 (C), 136.2 (C), 132.3 (C), 132.0 (C), 131.6 (CH), 131.1 (C), 130.4 (C), 130.2 (CH), 130.0
(CH), 129.8 (C), 129.4 (C), 128.7 (CH), 127.1 (CH), 125.5 (CH), 122.3 (CH), 122.1 (C), 119.0 (CH), 115.0
(CH). HRMS (m/z): [MH-] calcd. for C23H14ClN2O6: 449.0546; found 449.0542. (0.216 g, 66%)
4.3.2
2-(5-((1-(3-carboxyphenyl)-5-oxo-3-(trifluoromethyl)-1,5-dihydro-4H-pyrazol-4-ylidene)
methyl)furan-2-yl)-4-chlorobenzoic acid (3b): 1H NMR (400 MHz, DMSO-d6): δ 13.38 (s, COOH), 8.871
14

(d, J = 3.2 Hz, 1H), 8.439 (t, J = 1.6 Hz, 1H), 8.127 (d, J = 8.0 Hz, 1H), 8.079 (d, J = 1.2 Hz, 1H), 7.891 (d, J
= 7.6 Hz, 1H), 7.803 (d, J = 8.4 Hz, 1H), 7.718 ( m, 3H), 7.437 (d, J =3.2 Hz, 1H). 13C NMR (100 MHz,
DMSO-d6): 168.8 (C), 167.2 (C), 161.4 (C), 159.7 (C), 150.8 (C), 138.0 (C), 136.3 (C), 132.2 (C), 131.7 (CH),
131.4 (C), 130.6 (CH), 130.0 (CH), 129.1 (CH), 128.9, 127.2 (CH), 123.9 (CH), 120.4 (CH), 116.2 (CH),
115.3 (CH). HRMS(m/z): [MH+] calcd. for C23H13ClF3N2O6: 505.0420; found 505.0409. (0.119g, 59%)
4.3.3
2-(5-((1-(3-carboxyphenyl)-5-oxo-3-(trifluoromethyl)-1,5-dihydro-4H-pyrazol-4-ylidene)
1
methyl)furan-2-yl)benzoic acid (3c): (e/z mixture) H NMR (500 MHz, DMSO-d6): δ 13.29 (s, 2-COOH),
8.128 (d, J = 7.5 Hz, 1H), 7.949 ( d, J = 7.5 Hz, 1H), 7.880 (d, J = 8.0 Hz, 1H), 7.775 (d, J = 7.5 Hz, 1H),
7.703-7.606 (m, 4H), 7.359 (d, J = 4.0 Hz, 1H). 13C NMR (125 MHz, DMSO-d6): 169.6 (C), 167.2 (C),
162.0 (C), 161.5 (C), 150.6 (C), 138.1 (C), 132.8 (C), 132.2 (C), 131.6 (CH), 131.1 (CH), 130.5
(CH), 130.0 (CH), 129.7 (CH), 127.1 (CH), 127.0 (C), 123.9 (CH), 127.1 (C), 127.0 (C), 123.9
(C), 120.4 (CH), 115.4 (CH), 114.5 (C). HRMS (m/z): [MH-] calcd. for C23H13F3N2O6: 469.0647; found
469.0633. (0.020 g, 4%)
4.3.4
2-(5-((1-(3-carboxyphenyl)-5-oxo-3-phenyl-1,5-dihydro-4H-pyrazol-4-ylidene)methyl)furan-2-y
l)-4-chlorobenzoic acid (3d): 1H NMR (500 MHz, DMSO-d6): δ 13.29 (s, COOH), 8.800 (d, J = 3.7 Hz, 1H),
8.637 (t, J = 1.9 Hz, 1H), 8.264 (ddd, J = 8.3 Hz, 2.0 Hz, 0.9 Hz, 1H), 7.998 (d, J = 2.1 Hz, 1H), 7.816–7.753
(m, 4H), 7.733 (d, J = 8.3 Hz, 1H), 7.627-7.595 (m, 5H), 7.560 (s, 1H), 7.345 (d, J = 4.0 Hz, 1H). 13C NMR
(125 MHz, DMSO-d6): 168.9 (C), 167.4 (C), 162.3 (C), 157.6 (C), 152.3 (C), 151.0 (C), 138.8 (C), 136.1 (C),
132.0 (C), 131.5 (CH), 131.2 (C), 130.7 (C), 130.5 (CH), 130.1 (CH), 129.8 (CH), 129.6(CH), 129.1 (C), 129.0
(CH), 128.7 (CH), 128.0 (CH), 126.1 (CH), 122.9 (CH), 120.5 (C), 119.5 (CH), 115.3 (CH). HRMS (m/z):
[MH+] calcd. for C28H18ClN2O6: 513.09; found 513.0997. (0.145g, 71%)
4.3.5
4-chloro-2-(5-((3-methyl-5-oxo-1-phenyl-1,5-dihydro-4H-pyrazol-4-ylidene)methyl)furan-2-yl)b
enzoic acid (3e): 1H NMR (400 MHz, DMSO-d6): 8.690 (d, J = 4.0 Hz, 1H), 7.958-7.912 (m,3H), 7.779 (d,
15

J = 8.0 Hz, 1H), 7.645 (m, 2H), 7.460 (m, 2H), 7.278 (d, J = 4.0 Hz, 1H), 7.213 (m,2H), 2.475 (s, 3H –CH3),
13
2.321 (s, 3H, -CH3). C NMR (100 MHz, DMSO-d6): 168.9, 162.0, 156.9, 151.0, 138.7, 136.2, 132.3, 133.6
(CH), 131.1 (CH), 130.0 (CH), 129.8 (CH), 129.5 (CH), 129.4 (CH), 128.7 (CH), 126.9 (CH), 125.0 (CH),
122.4, 118.6 (CH), 118.3 (CH), 114.9 (CH), 114.6 (CH), 17.73, 13.30 (-CH3), 13.29 (-CH3). HRMS (m/z):
[MH-] calcd. for C22H14ClN2O4: 405.0642; found 405.0641.
4.3.6
4-chloro-2-(5-((5-oxo-1,3-diphenyl-1,5-dihydro-4H-pyrazol-4-ylidene)methyl)furan-2-yl)benzoi
c acid (3f): 1H NMR (500 MHz, DMSO-d6): δ 8.983 (d, J = 4.0 Hz, 1H), 8.193 (d, J = 7.5 Hz, 2H), 7.995(d, J
= 1.5 Hz, 1H), 7.922 (d, J = 8.5 Hz, 1H), 7.875-7.857 (m, 2H), 7.707 (s, 1H), 7.681-7.643 (m, 4H), 7.550 (t, J
13
= 8.5 Hz, 3H), 7.338 (d, J = 4..0 Hz, 1H), 7.307 (t, J = 7.0 Hz, 1H). C NMR (125 MHz, DMSO-d6): 169.0
(C), 162.2 (C), 157.5 (C), 152.0 (C), 151.0 (C), 138.6 (C), 136.1 (C), 131.6 (C), 131.5 (CH), 131.2 (CH), 130.8
(C), 130.4 (CH), 130.1 (CH), 129.6 (CH), 129.4 (CH), 129.2 (C), 129.1 (C), 129.0 (CH), 128.7 (CH), 127.7
(C), 125.5 (CH), 120.7 (C), 119.3 (CH), 115.2(CH). HRMS (m/z): [MH+] calcd. for C27H18ClN2O4: 469.0961;
found 469.0950. (0.187 g, 88%)
4.3.7
4-chloro-2-(5-((1-(4-fluorophenyl)-5-oxo-3-phenyl-1,5-dihydro-4H-pyrazol-4-ylidene)
methyl)furan-2-yl)benzoic acid (3g): 1H NMR (400 MHz, DMSO-d6): δ 13.44 (s, COOH), 8.768 (d, J = 4.0,
1H), 8.010-7.961 (m, 3H), 7.751-7.708 (m, 3H), 7.620-7.581 (m, 4H), 7.531 (s, 1H), 7.335-7.291 (m, 3H). 13C
NMR (100 MHz, DMSO-d6): 169.0 (C), 162.0 (C), 160.9 (C), 158.5 (C), 157.5 (C), 152.0 (C), 151.0 (C),
136.1 (C), 135.1 (C), 131.5 (CH), 131.3 (CH), 131.1 (C), 130.7 (C), 130.4 (CH), 130.1 (CH), 129.6 (CH),
129.1 (CH), 129.0 (C), 128.7 (CH), 127.8 (C), 121.3 (CH), 121.2 (CH), 120.5 (C), 116.2 (CH), 116.0 (CH),
115.2 (CH). HRMS (m/z): [MH-] calcd. for C27H15ClFN2O4: 485.0704; found 485.0691. (0.297 g, 76%)
4.3.8
4-chloro-2-(5-((1-(4-isopropylphenyl)-3-methyl-5-oxo-1,5-dihydro-4H-pyrazol-4-ylidene)
methyl)furan-2-yl)benzoic acid (3h): 1H NMR (400 MHz, DMSO-d6): δ 8.788 (d, J = 3.9 Hz, 1H), 7.989 (d,
J = 2.4 Hz, 1H), 7.892 (d, J = 8.8 Hz, 2H), 7.757-7.713 (m, 3H), 7.628-7.587 (m, 4H), 7.535 (s, 1H),
16

7.361-7.326 (m, 3H), 2.957-2.889 (sep, J = 17.1 Hz, 10.1 Hz, 3.3 Hz, 1H), 1.235 (d, J = 6.9 Hz, 6H). 13C
NMR (100 MHz, DMSO-d6): 169.0 (C), 162.0 (C), 157.4 (C), 151.7 (C), 151.0 (C), 145.8 (C), 136.4 (C),
136.1 (C), 131.5 (C), 131.1 (C), 130.8 (C), 130.3 (C), 130.1 (C), 129.6 (C), 129.2 (C), 129.0 (C), 128.7 (C),
127.6 (C), 127.2 (C),120.1 (C), 119.5 (C), 115.1 (C), 33.45 (CH-CH3), 24.35 (CH-CH3). HRMS (m/z): [MH-]
calcd. for C30H22ClN2O4: 509.1268; found 509.1242. (0.095 g, 47%)
4.3.9
(Z)-2-(5-((1-(4-(tert-butyl)phenyl)-5-oxo-3-phenyl-1,5-dihydro-4H-pyrazol-4-ylidene)methyl)fu
ran-2-yl)-4-chlorobenzoic acid (3i) 1H NMR (400 MHz, DMSO-d6): δ 8.794 (d, J= 3.8 Hz, 1H), 7.981 (d, J =
1.6 Hz, 1H), 7.902 (d, J = 8.8 Hz, 1H), 7.757 – 7.719 (m, 3H), 7.629 – 7.591 (m, 4H), 7.532 (s, 1H), 7.505 (d,
13
J = 8.8 Hz, 1H), 7.334 (d, J = 3.6 Hz, 1H), 1.311 (s, 1H). C NMR (100 MHz, DMSO-d6): 169.0 (C), 162.0
(C), 157.4 (C), 151.7 (C), 151.0 (C), 148.0 (C), 136.1 (C), 131.5 (CH), 131.1 (C), 131.0 (CH), 130.8 (C), 130.3
(CH), 130.1 (CH), 129.6 (CH), 129.2 (C), 129.0 (CH), 128.7 (CH), 127.6 (CH), 126.1 (C), 120.7 (C), 119.2
(CH), 115.15 (CH). HRMS (m/z): [MH-] calcd. for C31H24ClN2O4: 523.1430; found 523.1421. (0.065 g, 31%).
1
4.3.10 2,5-diphenyl-4-((5-phenylfuran-2-yl)methylene)-2,4-dihydro-3H-pyrazol-3-one (3j): H NMR
(400 MHz, DMSO-d6): 8.811 (d, J = 3.2 Hz, 1H), 8.034 (dd, J = 1.0 Hz, 8.4 Hz, 2H), 7.960 (d, J = 5.2 Hz,
2H), 7.766-7.747 (m, 2H), 7.631 (s, 1H), 7.617-7.585 (m, 3H), 7.521-7.441 (m, 6H), 7.243 (t, J = 7.2 Hz, 1H).
13C NMR (100 MHz, DMSO-d6): 162.5 (C), 160.4 (C), 151.9 (C), 150.7 (C), 138.6 (C), 131.1 (C), 130.8 (CH),
129.8 (CH), 129.6 (CH), 129.0 (CH), 129.0, 128.8 (CH), 128.7 (CH), 128.4 (CH), 125.2 (CH), 125.0 (CH),
120.2 (C), 119.3 (CH), 110.8(CH). HRMS (m/z): [MH-] calcd. for C26H19N2O2: 391.1447; found 391.1442.
(0.157 g, 69%)
4.3.11 3-(5-oxo-3-phenyl-4-((5-phenylfuran-2-yl)methylene)-4,5-dihydro-1H-pyrazol-1-yl)benzoic acid
(3k): 1H NMR (400 MHz, DMSO-d6): δ 13.14 (s, COOH) , 8.783 (d, J = 1.4 Hz, 1H), 8.623 (t, J = 1.8 Hz,
1H), 8.272 (m, 1H), 7.965 (m, 2H), 7.802 (m, 3H), 7.620 (m, 5H), 7.505 (m, 4H). 13C NMR (100 MHz,
DMSO-d6): 167.5 (C), 162.4 (C), 160.8 (C), 152.5 (C), 150.5 (C), 139.0 (C), 132.1 (C), 131.5 (CH), 130.9 (C),
17

130.7 (CH), 130.4 (CH), 129.7 (CH), 129.6 (CH), 129.3 (CH), 129.1 (CH), 128.8 (CH), 125.9 (CH), 125.8
(CH), 122.9 (CH), 119.4 (CH), 119.2 (C), 112.2 (CH). HRMS (m/z): [MH-] calcd. for C27H17N2O4: 433.1188;
found 433.1183. (0.069 g, 55%)
4.3.12 3-(3-methyl-5-oxo-4-((5-phenylfuran-2-yl)methylene)-4,5-dihydro-1H-pyrazol-1-yl)benzoic acid
1
(3l): (e/z mixture) H NMR (500 MHz, DMSO-d6): δ 8.699 (d, J = 3.4 Hz, 1H), 8.559 (s, 1H), 8.209 (d, J =
7.0 Hz, 1H), 7.978 (d, J = 7.5 Hz, 2H), 7.925 (d, J = 7.5 Hz, 1H), 7.813 (d, J = 4.0 Hz, 1H), 7.760 – 7.743 (m,
3H), 7.582-7.531 (m, 5H), 7.503-7.450 (m, 3H), 2.749 (s, [3/2] H), 2.358 (s, 3H). 13C NMR (125 MHz,
DMSO-d6): 162.3 (C), 161.5 (C), 160.1 (C), 151.7 (C), 150.5 (C), 150.0 (C), 148.7 (C), 139.0 (C), 132.0 (C),
131.6 (CH), 130.6 (CH), 130.5 (CH), 130.2 (CH), 129.9 (CH), 129.7 (C), 129.8 (C), 129.0 (C), 128.3 (CH),
127.1 (CH), 125.7 (CH), 125.6 (CH), 125.5 (CH), 122.3 (CH), 122.1 (CH), 121.0 (C), 119.4 (C), 119.0 (CH),
118.7 (CH), 111.9 (CH), 111.7 (CH), 18.32 (CH3), 13.33 (CH3). HRMS (m/z): [MH-] calcd. for C22H15N2O4:
371.1032; found 371.1028. (0.057 g, 53%)
4.1.13 2-(5-((5-oxo-1,3-diphenyl-1,5-dihydro-4H-pyrazol-4-ylidene)methyl)furan-2-yl)benzoic
acid
1
(3m): H NMR (400 MHz, DMSO-d6): δ 13.29 (s, COOH), 8.833 (d, J = 4.9 Hz, 1H), 8.024 (dd, J = 8.7Hz,
1.1 Hz, 2H), 7.890 (dd, J = 7.7 Hz, 0.7Hz, 1H), 7.775 (m, 2H), 7.725 (dd, J = 7.6 Hz, 1.2 Hz, 1H), 7.653 (m,
13
5H), 7.527 (m, 3H), 7.266 (m, 2H). C NMR (100 MHz, DMSO-d6): 169.8 (C), 162.3 (C), 159.6 (C), 152.0
(C), 150.8 (C), 138.7 (C), 132.6 (C), 131.5 (CH), 131.2 (CH), 130.9 (C), 130.5 (CH), 130.4 (CH), 129.6 (CH),
129.4 (CH), 129.3 (CH), 129.0 (CH), 128.6 (C), 128.1 (CH), 127.2 (C), 125.5 (C), 120.0 (C), 119.2 (C), 114.3
(C). HRMS (m/z): [MH-] calcd. for C27H17N2O4: 433.1188; found 433.174. (0.223 g, 50%)
4.1.14 2-(5-((1-(4-fluorophenyl)-5-oxo-3-phenyl-1,5-dihydro-4H-pyrazol-4-ylidene)methyl)furan-2-yl)
benzoic acid (3n): 1H NMR (500 MHz, DMSO-d6): 8.807 (d, J = 3.5 Hz, 1H), 8.021-7.993 (m, 2H), 7.866 (d,
J = 7.5 Hz, 1H), 7.750-7.704 (m, 3H), 7.651-7.547 (m, 5H), 7.509 (s, 1H), 7.332 (t, J = 9.0 Hz, 2H), 7.245 (d,
J = 3.5 Hz, 1H). 13C NMR (125 MHz, DMSO-d6): 169.9 (C), 162.1 (C), 160.6 (C), 159.6 (C), 152.0 (C), 150.8
18

(C), 135.1 (C), 132.6 (C), 131.4 (CH), 131.3 (CH), 130.8 (C), 130.4 (CH), 129.6 (CH), 129.5 (CH), 129.3 (C),
129.0 (CH), 128.6 (C), 128.2 (CH), 127.2 (C), 121.3 (CH), 121.2 (CH), 119.8, 116.2 (CH), 116.0 (CH), 114.3
(CH). HRMS (m/z): [MH-] calcd. for C27H16FN2O4: 451.1094; found 451.1095.
4.1.15 (Z)-2-(5-((1-(4-(tert-butyl)phenyl)-5-oxo-3-phenyl-1,5-dihydro-4H-pyrazol-4-ylidene)methyl)fu
ran-2-yl)benzoic acid (3p) 1H NMR (400 MHz, DMSO-d6): δ 8.834 (d, J = 3.9 Hz, 1H), 7.913 (t, J = 8.8 Hz,
13
3H), 7.764 – 7.704 (m, 3H), 7.672 – 7.495 (m, 9H), 7.263 (d, J = 4.0 Hz, 1H), 1.312 (s, 9H). C NMR (100
MHz, DMSO-d6): 169.8 (C), 162.1 (C), 159.5 (C), 151.7 (C), 150.8 (C), 148.0 (C), 136.2 (C), 132.6 (C), 131.5
(CH), 131.1 (CH), 130.9 (C), 130.4 (CH), 130.3 (CH), 129.6 (CH), 129.5 (CH), 129.3 (CH), 129.0 (CH), 128.0
(CH), 127.3 (C), 126.1 (CH), 120.1 (C), 119.2 (CH), 114.3 (CH). HRMS (m/z): [MH+] calcd. for C31H26N2O4:
491.1965; found 491.1969. (0.080 g, 44%)
4.1.16 2-(5-((1-(4-cyanophenyl)-5-oxo-3-phenyl-1,5-dihydro-4H-pyrazol-4-ylidene)methyl)furan-2-yl)
benzoic acid (3q): 1H NMR (400 MHz, DMSO-d6): δ 13.27 (s, COOH) , 8.784 (d, J = 3.9 Hz, 1H), 8.249
(d, J = 8.8 Hz, 2H), 7.947 (d, J = 8.8 Hz, 2H), 7.882 (d, J = 7.4 Hz, 1H), 7.771 (m, 2H), 7.722 (d, J = 7.2 Hz,
1H), 7.604 (m, 5H), 7.538 (s, 1H), 7.271 (d, J = 3.9 Hz, 1H). 13C NMR (100 MHz, DMSO-d6): 169.8 (C),
162.8 (C), 160.1 (C), 153.3 (C), 150.7 (C), 142.1 (C), 134.0 (C), 132.6 (C), 131.8 (C), 131.5 (C), 130.7 (C),
130.5 (C), 129.6 (C), 129.4 (C), 129.1 (C), 128.8 (C), 127.2 (C), 119.3 (C), 118.7 (C), 114.6 (C), 107.0 (C).
HRMS(m/z): [MH-] calcd. for C28H16N3O4: 458.1146; found 458.1137. (0.121 g, 66%)
4.1.17 2-(5-((1-(4-methoxyphenyl)-5-oxo-3-phenyl-1,5-dihydro-4H-pyrazol-4-ylidene)methyl)
furan-2-yl)benzoic acid (3r): 1H NMR (400 MHz, DMSO-d6): δ 13.26 (s, COOH) , 8.832 (d, J = 3.9 Hz,
1H), 7.884 (m, 3H), 7.758 (m, 3H), 7.650 (m, 5H), 7.509 (s, 1H), 7.252 (d, J = 4.0 Hz, 1H), 7.065 (m, 2H),
13
3.795 (s, 3H). C NMR (100 MHz, DMSO-d6): 169.8 (C), 161.8 (C), 159.4 (C), 157.1 (C), 150.8 (C), 132.6
(C), 131.9 (C), 131.4 (C), 131.0 (C), 130.4 (C), 130.3 (C), 129.6 (C), 129.5 (C), 129.3 (C), 129.0 (C), 127.9
19

(C), 127.3 (C), 121.3 (C), 120.1 (C), 114.5 (C), 114.2 (C), 55.78 (OCH3). HRMS(m/z): [MH-] calcd. for
C28H20N2O5: 463.1299; found 463.1284. (0.157 g, 85%)
1
4.1.18 3-(4-(furan-2-ylmethylene)-5-oxo-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzoic acid (3s): H
NMR (500 MHz, DMSO-d6): δ 13.09 (s, COOH), 8.735 (d, J = 4.0 Hz, 1H), 8.625 (t, J = 2.0 Hz, 1H), 8.289
(s, 1H), 8.260 (dd, J = 8.0 Hz, 1.0 Hz, 1H), 7.817 (d, J = 7.5 Hz, 1H), 7.779-7.761 (m, 2H), 7.625-7.592 (m,
5H), 6.981 (d, J = 3.5 Hz, 1H). 13C NMR (125 MHz, DMSO-d6): 172.5 (C), 167.5 (C), 162.4 (C), 152.5
(C), 151.7 (CH), 150.7 (C), 138.3 (C), 132.6 (CH), 132.1 (C), 130.6 (C), 130.5 (CH), 129.9
(CH), 129.6 (CH), 129.1 (CH), 126.4 (CH), 126.1 (CH), 123.0 (CH), 120.0 (C), 119.5 (CH),
115.9 (CH). HRMS (m/z): [MH+] calcd. for C21H15N2O4: 359.1037; found 359.1026. (0.094 g, 79%)
4.1.19 (Z)-3-(4-([1,1'-biphenyl]-4-ylmethylene)-5-oxo-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzoic
acid (3t): 1H NMR (400 MHz, DMSO-d6): δ 13.08 (s, COOH), 8.606 (dd, J = 2.0 Hz, 8.4 Hz, 3H), 8.205 (dd, J
= 2.4, 8.4 Hz, 1H), 7.855 - 7.727 (m, 8H), 7.575 - 7.543 (m, 4H), 7.492 (dt, J = 1.6 Hz, 7.2 Hz, 2H), 7.4147 –
7.3942 (m, 1H). 13C NMR (100 MHz, DMSO-d6): 167.0 (C), 162.3 (C), 162.2 (C), 153.6 (C), 151.4 (C), 149.9
(C), 145.2 (C), 139.2 (C), 138.8 (C), 136.2 (C), 134.5 (C), 132.6 (C), 132.0 (C), 131.3 (C), 130.7 (C), 130.4
(C), 129.7 (C), 128.9 (C), 128.3 (C), 127.9 (C), 126.7 (C), 126.3 (C), 125.4 (C), 122.3 (C), 120.6 (C), 118.8
(C). HRMS (m/z): [MH-] calcd. for C29H19N2O3: 443.1401; found 443.1389. (0.163 g, 52%).
4.1.20 (Z)-3-(4-(4-(benzyloxy)benzylidene)-5-oxo-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzoic
acid
1
(3u): H NMR (400 MHz, DMSO-d6): δ 13.14 (s, COOH), 8.630 – 8.617 (m, 3H), 8.245 – 8.216 (m, 1H),
7.801 – 7.740 (m, 1H), 7.731 – 7.716 (m, 3H), 7.602 – 7.563 (m, 4H), 7.482 – 7.461 (m, 2H), 7.423 – 7.343
(m, 3H), 7.200 (d, J = 9.2 Hz, 2H), 5.246 (s, 2H). 13C NMR (100 MHz, DMSO-d6): 167.5 (C), 163.6 (C),
162.6 (C), 153.8 (C), 151.1 (CH), 138.9 (C), 137.7 (CH), 136.7 (C), 132.0 (C), 130.9 (C), 130.4 (CH), 129.8
(CH), 129.5 (CH), 129.4 (CH),129.0 (CH), 128.6 (CH), 128.4 (CH), 126.5 (C), 126.0 (CH), 123.1 (CH), 122.7
20

(C), 119.6 (CH), 115.6 (CH), 70.22 (CH2). HRMS (m/z): [MH-] calcd. for C30H21N2O4: 473.1507; found
473.1501. (0.069 g, 53%).
4.2 Expression and purification of SARS-CoV and MERS-CoV 3CLpro
The expression and purification of SARS-CoV followed our reported procedure.[30] For expression of
MERS-CoV 3CLpro, the Factor Xa cleavage site (IEGR) and the 3CLpro (accession KJ361502.1, Ser3248 –
Gln3553) DNA sequence was synthesized and cloned into the pET32 expression vector by Mission Biotech.
Company (Taiwan) and was transformed into E. coli BL21 (DE3). A 10 ml overnight culture of a single
transformant was used to inoculate 1L of fresh LB medium containing 100 µg/ml ampicillin, The cells were
grown at 37 oC to A600=0.8 and induced with 0.4 mM isopropyl-β-thiogalactopyranoside (IPTG) for 22 h at 16
oC. The cells were harvested by centrifugation at 7000 X g for 15 min and the pellet was suspended in lysis
buffer (12 mM Tris-HCl, 120 mM NaCl, 0.1 mM EDTA, and 5mM DTT, pH 7.5). A French-press instrument
(Constant Cell Disruption System) was used to disrupt the cells at 20000 psi and centrifuged at 20000 X g for 1
h to discard the debris. The cell-free extract was loaded onto Ni-NTA column which was equilibrated with
lysis buffer containing 5 mM imidazole. After exhaustive washing with lysis buffer, the imidazole
concentration of the washing buffer was increased to 30 mM. The protein eluted by lysis buffer with 300 mM
imidazole were dialyzed against lysis buffer to removed imidazole and then Factor Xa was added to the fusion
o
proteins to a final concentration of 1% (w/w) and incubated at 16 C for 24 h to remove the His-tag.
Subsequently, the processed MERS-CoV 3CLpro was passed through a Ni-NTA column for purification. The
protein concentration was determined by the protein assay kit (BioRad, USA) and BSA was used as standard.
4.3 Measurement of IC50
A fluorometric assay[30] was utilized to determine the inhibition constants of the prepared samples. Fluorogenic
peptide, Dabcyl-KTSAVLQSGFRKME-Edans, was used as the substrate, and the enhanced fluorescence due
to the cleavage of this substrate catalyzed by the 3CLpro was monitored at 538 nm with excitation at 355 nm.
21

The IC50 value of the individual sample was measured in a reaction mixture containing 50 nM SARS 3CLpro or
300 nM MERS-Cov 3CLpro and 10 μM of the fluorogenic substrate in 20 mM Bis-Tris (pH 7.0).
5. Acknowledgement
This work was supported by Academia Sinica.
6. References and notes
[1] P.A. Rota, M.S. Oberste, S.S. Monroe, W.A. Nix, R. Campagnoli, J.P. Icenogle, S. Penaranda, B.
Bankamp, K. Maher, M.H. Chen, S. Tong, A. Tamin, L. Lowe, M. Frace, J.L. DeRisi, Q. Chen, D. Wang, D.D.
Erdman, T.C. Peret, C. Burns, T.G. Ksiazek, P.E. Rollin, A. Sanchez, S. Liffick, B. Holloway, J. Limor, K.
McCaustland, M. Olsen-Rasmussen, R. Fouchier, S. Gunther, A.D. Osterhaus, C. Drosten, M.A. Pallansch,
L.J. Anderson, W.J. Bellini, Characterization of a novel coronavirus associated with severe acute respiratory
syndrome, Science. 300 (2003) 1394-1399.
[2] V. Thiel, J. Herold, B. Schelle, S.G. Siddell, Viral replicase gene products suffice for coronavirus
discontinuous transcription, J. Virol. 75 (2001) 6676-6681.
[3] V. Thiel, K.A. Ivanov, A. Putics, T. Hertzig, B. Schelle, S. Bayer, B. Weissbrich, E.J. Snijder, H. Rabenau,
H.W. Doerr, A.E. Gorbalenya, J. Ziebuhr, Mechanisms and enzymes involved in SARS coronavirus genome
expression, J. Gen. Virol. 84 (2003) 2305-2315.
[4] C. J. Kuo, P. H. Liang, Characterization and Inhibition of the Main Protease of Severe Acute Respiratory
Syndrome Coronavirus, ChemBioEng. Rev. 2 (2015) 118-132.
[5] V. Kumar, Y.S. Jung, P.H. Liang, Anti-SARS coronavirus agents: a patent review (2008 - present), Expert
Opin. Ther. Pat. 23 (2013) 1337-1348.
[6] Y.M. Baez-Santos, S.E. St John, A.D. Mesecar, The SARS-coronavirus papain-like protease: structure,
function and inhibition by designed antiviral compounds, Antivir. Res. 115 (2015) 21-38.
22

[7] R. Ramajayam, K.P. Tan, P.H. Liang, Recent development of 3C and 3CL protease inhibitors for
anti-coronavirus and anti-picornavirus drug discovery, Biochem. Soc. Trans. 39 (2011) 1371-1375.
[8] Q. Zhao, E. Weber, H. Yang, Recent developments on coronavirus main protease/3C like protease
inhibitors, Recent Pat. Antiinfect. Drug Discov. 8 (2013) 150-156.
[9] T.R. Tong, Therapies for coronaviruses. Part 2: Inhibitors of intracellular life cycle, Expert Opin. Ther. Pat.
19 (2009) 415-431.
[10] R. Hilgenfeld, M. Peiris, From SARS to MERS: 10 years of research on highly pathogenic human
coronaviruses, Antivir. Res. 100 (2013) 286-295.
[11]
WHO,
Middle
East
respiratory
syndrome
coronavirus
(MERS-CoV),
http://www.who.int/mediacentre/factsheets/mers-cov/en/ (10.05.16).
[12] S. Tomar, M.L. Johnston, S.E. St John, H.L. Osswald, P.R. Nyalapatla, L.N. Paul, A.K. Ghosh, M.R.
Denison, A.D. Mesecar, Ligand-induced dimerization of Middle East Respiratory Syndrome (MERS)
coronavirus NSP5 protease (3CLpro): Implications for NSP5 regulation and the development of antivirals, J.
Biol. Chem. 290 (2015) 19403-19422.
[13] A. Kilianski, S.C. Baker, Cell-based antiviral screening against coronaviruses: Developing virus-specific
and broad-spectrum inhibitors, Antivir. Res. 101 (2014) 105-112.
[14] D.L. Barnard, Y. Kumaki, Recent developments in anti-severe acute respiratory syndrome coronavirus
chemotherapy, Future Virol. 6 (2011) 615-631.
[15] R.M. Krug, R. A. Lamb, Orthomyxoviridae: the viruses and their replication, (4th eds.), Lippincott
Williams and Wilkins, Philadelphia 2001.
[16] Y. Watanabe, M.S. Ibrahim, Y. Suzuki, K. Ikuta, The changing nature of avian influenza A virus (H5N1),
Trends Microbiol. 20 (2012) 11-20.
[17] J.K. Taubenberger, D.M. Morens, 1918 Influenza: The mother of all pandemics, Emer. infect. dis. 12
(2006) 15-22.
23

[18] R.B. Gao, B. Cao, Y.W. Hu, Z.J. Feng, D.Y. Wang, W.F. Hu, J. Chen, Z.J. Jie, H.B. Qiu, K. Xu, X.W.
Xu, H.Z. Lu, W.F. Zhu, Z.C. Gao, N.J. Xiang, Y.Z. Shen, Z.B. He, Y. Gu, Z.Y. Zhang, Y. Yang, X. Zhao, L.
Zhou, X.D. Li, S.M. Zou, Y. Zhang, X.Y. Li, L. Yang, J.F. Guo, J. Dong, Q. Li, L.B. Dong, Y. Zhu, T. Bai,
S.W. Wang, P. Hao, W.Z. Yang, Y.P. Zhang, J. Han, H.J. Yu, D.X. Li, G.F. Gao, G.Z. Wu, Y. Wang, Z.H.
Yuan, Y.L. Shu, Human infection with a novel avian-origin Influenza A (H7N9) Virus, N. Eng. J. Med. 368
368 (2013) 1888-1897.
[19] CDC. Avian Influenza A (H7N9) Virus. http://www.cdc.gov/flu/avianflu/h7n9-virus.htm (accessed
10.05.16).
[20] V. Kumar, C.K. Chang, K.P. Tan, Y.S. Jung, S.H. Chen, Y.S. Cheng, P.H. Liang, Identification, synthesis,
and evaluation of new neuraminidase inhibitors, Org. lett. 16 (2014) 5060-5063.
[21] R. Ramajayam, K.P. Tan, H.G. Liu, P.H. Liang, Synthesis and evaluation of pyrazolone compounds as
SARS-coronavirus 3C-like protease inhibitors, Bioorg. Med. Chem. 18 (2010) 7849-7854.
[22] L. Racane, V. Tralic-Kulenovic, D.W. Boykin, G. Karminski-Zamola, Synthesis of new cyano-substituted
bis-benzothiazolyl arylfurans and arylthiophenes, Molecules, 8 (2003) 342-348.
[23] K. Fan, P. Wei, Q. Feng, S. Chen, C. Huang, L. Ma, B. Lai, J. Pei, Y. Liu, J. Chen, L. Lai, Biosynthesis,
purification, and substrate specificity of severe acute respiratory syndrome coronavirus 3C-like proteinase, The
J. Biol. Chem. 279 (2004) 1637-1642.
[24] M.F. Hsu, C.J. Kuo, K.T. Chang, H.C. Chang, C.C. Chou, T.P. Ko, H.L. Shr, G.G. Chang, A.H.J. Wang,
P.H. Liang, Mechanism of the maturation process of SARS-CoV 3CL protease, J. Biol. Chem. 280 (2005)
31257-31266.
[25] T.C. Hu, Y. Zhang, L.W. Li, K.F. Wang, S. Chen, J. Chen, J.P. Ding, H.L. Jiang, X. Shen, Two adjacent
mutations on the dimer interface of SARS coronavirus 3C-like protease cause different conformational changes
in crystal structure, Virology. 388 (2009) 324-334.
24

[26] J.M. Sisk, M.B. Frieman, Screening of FDA-approved drugs for treatment of emerging pathogens, ACS
Infect. Dis. 1 (2015) 401-402.
[27] A.H. de Wilde, D. Jochmans, C.C. Posthuma, J.C. Zevenhoven-Dobbe, S. van Nieuwkoop, T.M.
Bestebroer, B.G. van den Hoogen, J. Neyts, E.J. Snijder, Screening of an FDA-Approved compound library
identifies four small-molecule inhibitors of Middle East Respiratory Syndrome Coronavirus replication in cell
culture, Antimicrob. Agents Chemother. 58 (2014) 4875-4884.
[28] J. Dyall, C.M. Coleman, B.J. Hart, T. Venkataraman, M.R. Holbrook, J. Kindrachuk, R.F. Johnson, G.G.
Olinger, P.B. Jahrling, M. Laidlaw, L.M. Johansen, C.M. Lear-Rooney, P.J. Glass, L.E. Hensley, M.B.
Frieman, Repurposing of clinically developed drugs for treatment of Middle East Respiratory Syndrome
coronavirus infection, Antimicrob. Agents Chemother. 58 (2014) 4885-4893.
[29] C.J. Kuo, H.G. Liu, Y.K. Lo, C.M. Seong, K.I. Lee, Y.S. Jung, P.H. Liang, Individual and common
inhibitors of coronavirus and picornavirus main proteases, FEBS Lett. 583 (2009) 549-555.
[30] C.J. Kuo, Y.H. Chi, J.T. Hsu, P.H. Liang, Characterization of SARS main protease and inhibitor assay
using a fluorogenic substrate, Biochem. Biophys. Res. Commun. 318 (2004) 862-867.
25

Graphical Abstract:
Leave this area blank for abstract info.
Identification, synthesis and evaluation of
SARS-CoV and MERS-CoV 3C-like protease
inhibitors
Vathan Kumar,a Kian-Pin Tan,a Ying-Ming Wang,a Sheng-Wei Lin,a Po-Huang Liang a,b,*
aInstitute of Biological Chemistry, Academia Sinica, Taipei 115, Taiwan
bInstitute of Biochemical Sciences, National Taiwan University, Taipei 106, Taiwan
Ring B could be
changed to other ring
Must be bulky group
-COOH is important
→COOH important if ring A is unsubstituted.
→Bulky side chain ↑ activity.
Halogen is not important if R4 is bulky substituent
→Electron withdrawing group ↓ activity.
26